2nd generation OvPlex panel completes initial phase II biomarker trial
10-12-2008
HealthLinx Limited has completed an initial Phase II biomarker trial on its second generation ovarian cancer diagnostic that has increased the diagnostic efficiency of the panel to 98 per cent for early stage diagnosis. This compares with the world’s most commonly used diagnostic CA125 with ...
30-10-2008
There is new hope for women around the world, with the launch of an early detection test for ovarian cancer, according to HealthLinx Limited. The test, developed in Melbourne by HealthLinx scientists in collaboration with ARL Pathology, is called the OvPlex™ Panel and works by identifying ...
Investment merit prevails in pessimistic market
28-10-2008
Fluorotechnics Limited has successfully closed its initial public offering (IPO) raising nearly $8 million. The company comfortably passed its minimum $6 million target. Fluorotechnics has been supported by institutional investors from Asia, Australia and Europe as well as professional and ...
05-09-2008
The new Monash Antibody Technologies Facility (MATF) was officially opened at a ceremony attended by a number of dignitaries from the Australian government, academia and the life science industry. The newly refurbished, two hundred square meter facility houses cutting-edge equipment and ...
11-07-2008
Coat color of wild and domestic animals is a critical trait that has significant biological and economic impact. In a study published online in Genome Research, researchers have identified the genetic basis for black coat color, and white, in a breed of domestic sheep. In the wild, mammalian ...
